Approval · Notice of Compliance 29492 · 2022
THYROKARE: Notice of Compliance 29492
Issued November 18, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29492
- Date
- November 18, 2022
- Company
- Neogen CorporationLansing, Michigan, United States
- Product type
- Veterinary
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| THYROKARE | 02532743 | Cancelled Pre Market |
| THYROKARE | 02532751 | Cancelled Pre Market |
| THYROKARE | 02532778 | Cancelled Pre Market |
| THYROKARE | 02532786 | Cancelled Pre Market |
| THYROKARE | 02532794 | Cancelled Pre Market |
| THYROKARE | 02532808 | Cancelled Pre Market |
| THYROKARE | 02532816 | Cancelled Pre Market |
| THYROKARE | 02532824 | Cancelled Pre Market |
| THYROKARE | 02532832 | Cancelled Pre Market |
Medicinal ingredients
- LEVOTHYROXINE SODIUM 0.1 MG per TAB
- LEVOTHYROXINE SODIUM 0.2 MG per TAB
- LEVOTHYROXINE SODIUM 0.3 MG per TAB
- LEVOTHYROXINE SODIUM 0.4 MG per TAB
- LEVOTHYROXINE SODIUM 0.5 MG per TAB
- LEVOTHYROXINE SODIUM 0.6 MG per TAB
- LEVOTHYROXINE SODIUM 0.7 MG per TAB
- LEVOTHYROXINE SODIUM 0.8 MG per TAB
- LEVOTHYROXINE SODIUM 1 MG per TAB